Skip to content

Clinical trials

Completed Phase 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Phase: Phase 2 Status: Completed Clear all

172 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20008
20016
200210
20038
20049
200513
20067
20079
20089
200912
20106
20115
20127
20139
20145
20157
20163
20177
20184
20193
20204
20212
20222
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed172

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center23
Fred Hutchinson Cancer Center13
National Heart, Lung, and Blood Institute (NHLBI)13
Novartis Pharmaceuticals10
National Cancer Institute (NCI)7
Bristol-Myers Squibb6
Gruppo Italiano Malattie EMatologiche dell'Adulto5
Masonic Cancer Center, University of Minnesota4
Astex Pharmaceuticals, Inc.3
Northside Hospital, Inc.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive172
Leukemia, Myeloid, Acute73
Precursor Cell Lymphoblastic Leukemia-Lymphoma66
Myelodysplastic Syndromes61
Leukemia49
Leukemia, Lymphocytic, Chronic, B-Cell38
Lymphoma, Non-Hodgkin38
Hodgkin Disease36
Leukemia, Myeloid, Chronic-Phase33
Multiple Myeloma27

Trials

Showing 1 to 25 of 172. Each trial links to its page on Pharma Observatory.

72 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.